Roche won U.S. FDA 510(k) clearance for new lab automation modules, while also receiving CE marking for a blood donor screening assay. The Cobas c 703 and Cobas ISE Neo units expand throughput within Roche Diagnostics’ Cobas Pro Integrated Solutions platform, targeting bottlenecks including staff shortages and rising test volumes. Roche said the Cobas c 703 unit can deliver up to 2,000 tests per hour with expanded reagent capacity, and the Cobas ISE Neo supports up to 1,800 tests per hour. The company’s molecular Cobas MPX-E assay also received CE marking for 4-in-1 blood donor screening that consolidates detection of multiple viral targets. The approvals reinforce continued platform investment aimed at improving workflow efficiency and reducing manual handling in high-volume clinical labs.